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Abstract
The MYC oncogene has been implicated in the regulation of up to thousands of genes involved in many cellular programs
including proliferation, growth, differentiation, self-renewal, and apoptosis. MYC is thought to induce cancer through an
exaggerated effect on these physiologic programs. Which of these genes are responsible for the ability of MYC to initiate
and/or maintain tumorigenesis is not clear. Previously, we have shown that upon brief MYC inactivation, some tumors
undergo sustained regression. Here we demonstrate that upon MYC inactivation there are global permanent changes in
gene expression detected by microarray analysis. By applying StepMiner analysis, we identified genes whose expression
most strongly correlated with the ability of MYC to induce a neoplastic state. Notably, genes were identified that exhibited
permanent changes in mRNA expression upon MYC inactivation. Importantly, permanent changes in gene expression could
be shown by chromatin immunoprecipitation (ChIP) to be associated with permanent changes in the ability of MYC to bind
to the promoter regions. Our list of candidate genes associated with tumor maintenance was further refined by comparing
our analysis with other published results to generate a gene signature associated with MYC-induced tumorigenesis in mice.
To validate the role of gene signatures associated with MYC in human tumorigenesis, we examined the expression of
human homologs in 273 published human lymphoma microarray datasets in Affymetrix U133A format. One large functional
group of these genes included the ribosomal structural proteins. In addition, we identified a group of genes involved in a
diverse array of cellular functions including: BZW2, H2AFY, SFRS3, NAP1L1, NOLA2, UBE2D2, CCNG1, LIFR, FABP3, and EDG1.
Hence, through our analysis of gene expression in murine tumor models and human lymphomas, we have identified a novel
gene signature correlated with the ability of MYC to maintain tumorigenesis.
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Introduction
Overexpression of MYC is one of the most frequent events in
human tumorigenesis [1].MYCoverexpression isthought to induce
tumorigenesis by causing inappropriate gene expression resulting in
autonomous cellular growth, proliferation, and the inhibition of
cellular differentiation [2,3]. Many laboratories have conditionally
overexpressed c-MYC (MYC) utilizing conditional transgenic
model systems [4–9]. In these models, the suppression of MYC
led to permanent loss of tumorigenesis through proliferative arrest,
differentiation and/or apoptosis [4–6,10]. In some circumstances,
even the brief suppression of MYC overexpression permanently
prevents its ability to sustain tumorigenesis [6]. These and other
observations have suggested the possibility that oncogenes such as
MYCexhibitthephenomenaofoncogeneaddiction[11].However,
the molecular basis of oncogene addiction is not clear. Recently, we
have suggested that cellular senescence, which involves chromatin
modifications and heterochromatin formation [12,13], may be an
important mechanism for sustained tumor regression upon MYC
inactivation [14].
MYC is thought to play a role in the regulation of up to 15% of
genes in the fly, mouse or human [3,15,16]. Thus, it seems likely
that changes in gene expression programs, rather than individual
genes, account for the phenotypic consequences of MYC
inactivation. Consistent with this notion, MYC has recently been
shown to globally influence chromatin structure through histone
modifications [17–19]. Similarly, N-MYC was shown to globally
regulate acetylation and methylation of histone molecules [20].
We have reported that MYC inactivation in tumors induces
specific global changes in histone modification [14]. Although
many MYC target genes have been identified in various cells or
tissue contexts (summarized in http://www.myc-cancer-gene.org),
it is hard to discern which of the many of MYC targets are
associated with the ability of MYC to initiate and/or sustain
tumorigenesis.
Many previous studies have examined changes in gene
expression associated with the induction of MYC expression in
cells [3,15,21–26]. Other groups have performed comparative
analysis of gene expression profiles between murine constitutive
MYC-induced tumors and human tumors in liver and prostate
PLoS Genetics | www.plosgenetics.org 1 June 2008 | Volume 4 | Issue 6 | e1000090cancers [27,28]. Both of these analyses identified similarities in
gene expression between MYC-induced tumor models and human
tumors. Although revealing, these studies would not necessarily
identify gene products that are responsible for the ability of MYC
to induce tumorigenesis. We speculated that by analyzing gene
expression profiles in tumors generated from conditional trans-
genic models would allow us to identify gene expression signature
specifically associated with the ability of MYC to initiate and
maintain tumorigenesis. We performed microarrays on mRNA
samples from a time-course experiment with MYC inactivated and
then reactivated in osteosarcoma. The expression data was then
examined using the StepMiner algorithm [29] to generate a list of
genes associated with MYC-induced tumorigenesis in osteosarco-
mas (Figure 1). The StepMiner algorithm analyzes microarray
time courses by identifying genes that undergo abrupt transitions
in expression level, and the time at which the transitions occur.
Importantly, by ChIP we were able to demonstrate that
permanent changes in gene expression were frequently associated
with measurable alterations in the ability of MYC to bind to the
promoter regions of these genes in osteosarcomas. Furthermore,
gene expression profiles were compared between osteosarcomas
and the previously published MYC conditional pancreatic tumor
[25] to generate a common gene signature associated with MYC-
induced tumorigenesis in mice (Figure 1). Finally, Boolean analysis
was used to further examine the correlation between levels of
expression of this identified subset of genes among the published
dataset of 7,171 human microarrays in U133A format. From this
analysis, we were able to deduce a list of genes strongly correlated
with the ability of MYC to maintain tumorigenesis.
Results
MYC Inactivation and Reactivation Induces Global
Changes in Gene Expression Identified by the StepMiner
Algorithm
The MYC induced osteosarcoma derived cell line, 1325, was
grown in vitro [6] and treated with 20ng/ml of doxycycline in
complete DMEM medium for various length of time to inactivate
MYC expression. To reactivate MYC expression, doxycyline was
removed by rinsing the bone tumor cells with an excess amount of
PBS. mRNA was collected from bone tumor cells treated with
doxycycline for 0, 4, 8, 12, 18, 24, 36, and 48 hours, and after
removal of doxycycline for 4 , 8, 12, 18, 24, 36, and 48 hours.
MYC levels were greatly reduced as early as 4 hours after
doxycycline treatment (Figure 2A and Figure S1). We confirmed
that the expression of MYC could be reactivated to a level similar
to that of MYC-on tumors by thoroughly washing the cells with
PBS (Figure 2A and Figure S1).
cDNA microarray analysis was performed on the RNA samples
prepared from tumors in which MYC was inactivated and
reactivated for different lengths of time. StepMiner analysis
(Figure 2B, 2C) [29] was applied to this time-course microarray
experiment to identify changes in gene expression at discrete time
points before and after MYC inactivation and reactivation.
StepMiner fits step functions to the data points using an adaptive
regression scheme and identifies time points at which a gene is
significantly induced or repressed. Examples of one-step expres-
sion pattern are illustrated in Figure 2C.
Recently, we have shown that MYC inactivation generally
induces cellular senescence in several tumor models [14].
Therefore, we specifically examined if the expression of senescence
associated genes changed upon MYC inactivation in osteosarco-
mas. Indeed, we did find that senescence associated genes such as
p15INK4b, p21CIP, PCNA, MCM3, CYCLIN A [12,30,31] were
Author Summary
The targeted inactivation of oncogenes may be a specific
and effective treatment of cancer. However, how onco-
gene inactivation leads to tumor regression is not clear.
Previously, we have shown that even the brief inactivation
of the MYC oncogene can result in the sustained
regression of at least some tumors. To understand the
mechanism, we have utilized several novel genomic
analyses to define a set of genes that strongly correlate
with the ability of the MYC oncogene to maintain
tumorigenesis. First, we generated a novel data set from
microarray analyses of murine tumors that we analyzed by
StepMiner to identify discrete step changes in gene
expression after the inactivation or the reactivation of
the MYC oncogene. Second, we utilized Boolean Network
Analysis to further define the subset of genes highly
correlated with MYC in human tumorigenesis. Third, we
utilized ChIP analysis to demonstrate that in many cases
the permanent changes of gene expression we uncovered
were associated with changes in the ability of MYC to
occupy the promoter locus. Our general strategy could be
similarly utilized in other experimental model systems to
understand how specific oncogenes contribute to the
maintenance of tumorigenesis.
Figure 1. Overview of our general strategy to define a gene signature associated with the ability of MYC to initiate and maintain
tumorigenesis.
doi:10.1371/journal.pgen.1000090.g001
Gene Signature Associated with Tumorigenesis
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S2 and Table S1). Thus, our results support the notion that MYC
inactivation is inducing changes in gene expression that is
associated with cellular senescence.
Generally, analysis of gene expression changes after StepMiner
analysis revealed four discrete patterns of changes in gene
expression upon MYC inactivation and reactivation: Permanently
Repressed (PR), Permanently Induced (PI), Reversibly Repressed
(RR) and Reversibly Induced (RI). For this analysis, we set p,0.01
as a cutoff for statistically significant changes in gene expression.
We identified 1016 unique probes in the PR group, 1777 unique
probes in the PI group, 1148 unique probes in the RI group, and
1167 unique probes in the RR group (Figure 3 and Tables S2 for
lists of genes).
Based upon our previously published observation that even brief
inactivation of MYC can result in the sustained loss of the
neoplastic properties of MYC-induced osteosarcomas [6], we
speculated that genes which are potentially important for sustained
tumorigenesis would be permanently repressed or induced (e.g. the
PR group or the PI group) upon MYC inactivation.
To identify associated functional activities associated with the
PR and PI groups of genes, we applied Gene Ontology analysis
(GO Term analysis) to the list of genes generated above. Biological
functions that were identified for each step upon MYC
inactivation are listed (Table S3, S4, and S5). Associated functions
identified include gene products known to regulate metabolism,
biosynthesis of nucleotides and proteins and genes involved in the
regulation or function of ribonucleoprotein complexes.
Figure 2. Microarray data analysis for gene expression in osteosarcomas upon MYC inactivation and reactivation by the StepMiner
algorithm. (A) Quantitative Real-time PCRs for MYC Transgene Expression (Human cMYC) upon treatments and removals of doxycycline in Bone
Tumor Cells. Bone tumor cells 1325 were treated with 20ng/ml of doxycycline for 0, 4, 8, 12, 18, 24, 36 and 48 hours before collecting total RNA.
Excess amount of PBS was applied to cells treated with doxycyline for 48 hours to remove doxycycline. At 4, 8, 12, 18, 24, 36 and 48 hours after
removing doxycycline, cells were collected for total RNA by Trizol and cDNA was synthesized by Superscript II. cDNA templates from all these samples
were used for quantitative real-time PCR with fluorescence labeled human c-MYC and mouse GAPDH probes to validate MYC expression. MYC
expression at each time point was normalized with the MYC expression in the original tumor before doxycycline treatment. (B) Raw data from the
microarray experiments at different time points was applied with StepMiner analysis to find the patterns of interest (expression went down upon
MYC inactivation and stayed down upon MYC reactivation, expression went up upon MYC inactivation and stayed up upon MYC reactivation).
p,0.01 was set to be the cutoff for significant changes among experiments. (C) Examples of StepMiner analysis are shown. In left panels, x-axis is the
array number (MYC inactivation for 0 hour=1, 4 hour=2, 8 hour=3, 12 hour=4, 18 hour=5, 24 hour=6, 36 hour=7, 48 hour=8, MYC reactivation
for 4 hour=9, 8 hour=10, 12 hour=11, 18 hour=12, 24 hour=13, 36 hour=14, 48 hour=15. ) and y-axis is the level of mRNA expression
compared with reference RNA. Typical one step changes are listed for Atp11a and Dnmt2 (p=2.97610
26 and p=1.25610
24 expression went up
upon MYC inactivation and stayed up for MYC reactivation). Centering the data with the expression level at the identified step was applied for
illustration purposes.
doi:10.1371/journal.pgen.1000090.g002
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ribosomal structure proteins and ribosomal RNAs [18,32]. Hence,
it is striking that the mRNA expression of 61 ribosomal structural
proteins out of 82 ribosomal structural protein genes was decreased
upon MYC inactivation and further decreased upon MYC
reactivation in bone tumor (see Figure 4A and Table S3 for results
of GO term analysis). To validate that these genes expression did
change, we performed quantitative real-time PCR of 11 ribosomal
structural proteins in osteosarcomas (Figure 4B). Moreover, we
found that the same ribosomal structural proteins also changed
upon MYC inactivation in our conditional model of lymphomas [4]
(Figure 4B). We then examined if the decreased expression of
ribosomal structural proteins associated with changes in rate of
protein synthesis. We found that the protein synthesis rates were
decreased in both bone tumor and lymphomas upon MYC
inactivation (Figure 4C). Furthermore, the protein synthesis rate
remained loweduponMYCreactivationinbonetumor(Figure4C).
MYC has been shown to regulate the gene expression of a
multitude of genes [3,15,21–26,33–35]. To examine if these genes
changed in gene expression upon MYC inactivation and
reactivation, we used two approaches. First, we retrieved the
mouse homologs of MYC target genes listed in www.myc-cancer-
gene.org, a collection of most of the published MYC target genes
in different organisms and tissues (total of 1697 MYC targets)[16].
In osteosarcomas, 71 of the published MYC targets are
permanently induced and 52 of the published MYC targets are
permanently repressed upon MYC inactivation and reactivation
(p,0.01) (Figure 5, see PR and PI). Second, we examined direct
MYC target genes identified as defined by several recent
publications [33–35]. Interestingly, only 7–11% of these identified
direct MYC target genes exhibited sustained changes upon MYC
inactivation in osteosarcoma (Figure 6 and Table S6).
MYC Binding to Promoter Loci Correlated with
Permanent Changes in Gene Expression
An important recent report suggests that MYC binding to
promoters is regulated by the chromatin structure at these gene
Figure 3. Permanent and reversible changes of gene expression upon MYC inactivation in osteosarcomas identified by the
StepMiner algorithm. Statistically significant changes (p,0.01) with specific patterns are listed here: 1777 probes with expression went up after
MYC inactivation and stayed up upon MYC reactivation (the PI group), 1016 probes with expression went down after MYC inactivation and remained
down upon MYC reactivation (the PR group), 1148 probes with expression went up after MYC inactivation and went back down upon MYC
reactivation (the RI group) and 1167 probes with expression went down after MYC inactivation and went back up upon MYC reactivation (the RR
group). Lists of gene names in each group are shown in Table S2. Pie Charts summarizing numbers of genes in each group are shown in
supplementary Figure 3.
doi:10.1371/journal.pgen.1000090.g003
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associated with global changes in chromatin structures [14]. Thus,
it seemed that a possible explanation for the permanent changes in
gene expression that we observed (Figure 3) is that the ability of
MYC to bind to specific gene products is perturbed by changes in
chromatin structure. To address this possibility directly, we used
ChIP to examine MYC binding to E-box sequences of target genes
in MYC activated and MYC reactivated conditions for osteosar-
comas.
We specifically examine three groups of genes: the ribosomal
structural proteins (Figure 4), the PR group (Figure 6, [35]) and the
RR group genes that were identified previously as direct MYC
targets before (Figure 6, [35]). A total of 168 E-box regions were
examined by ChIP. As a control, we performed ChIP for
osteosarcoma in the MYC OFF condition (Table S7). Binding of
MYC to E-box regions is shown as the percentage of DNA
brought down by ChIP for the MYC ON versus the MYC
reactivated conditions (Figure 7). Note, that upon MYC
reactivation the majority of ribosomal structural genes exhibited
decreased MYC binding to E-boxes relative to the MYC ON
condition (31 out of 41 data points fall below the line of X=Y, p-
value=4.34610
24). Similarly, the majority of the genes with the
PR pattern of gene expression exhibited a significant decrease of
MYC binding to E-boxes relative to the MYC ON condition (42
out of 60 data points fall below the line of X=Y, p-value=0.0016)
when MYC was reactivated (Figure 7 and Table S7). In contrast,
the group of genes that exhibited the RR pattern of gene
expression exhibited no particular increase or decrease in MYC
binding to E-boxes compared with the MYC ON condition (33
out of 67 data points fall below the line of X=Y, p-value=0.4).
Our results support the possibility that the permanent changes in
gene expression upon MYC inactivation can be explained in many
cases because of a change in the ability of MYC to bind to specific
promoter loci.
Comparative Analysis of Osteosarcoma Microarray Data
to a Previously Published Microarray Dataset
To determine if the gene signature we identified would also be
seen in another tumor model system, we compared our microarray
data from MYC-induced osteosarcoma with a previously reported
microarray data set from a MYC-induced pancreatic tumor model
to identify a common expression signature for MYC-induced
tumorigenesis [25]. In the published report, MYC-ER
TAM was
expressed specifically in b-cell pancreatic tissues with MYC-on for
2, 4, 8, 24 hours, and 21 days (referred as tumorigenesis arrays in
the published paper), and MYC off in pancreatic tumors for 2, 4,
and 6 days (referred as tumor regression arrays in the published
paper). MYC activation induced pancreatic tumors and MYC
inactivation resulted in tumor regression through apoptosis [7].
cDNA from these samples was applied to oligo arrays from
Affymetrix [25]. As previously suggested in the paper, we assumed
that genes were induced (repressed) upon MYC activation and
repressed (induced) upon MYC inactivation were potentially
important for MYC induced tumorigenesis.
We first used the StepMiner algorithm was applied to the raw
data generated from these published experiments to obtain lists of
genes that increase (or decrease) in expression upon tumorigenesis
and decrease (or increase) in expression upon tumor regression
(Figure 8 and Table S8). After StepMiner analysis, 196 and 65
unique probes were identified as induced and repressed genes
respectively, which are associated with MYC-induced tumorigen-
Figure 4. mRNA expression of ribosomal structural proteins and the associated rates of protein synthesis were reduced upon MYC
inactivation in osteosarcomas and lymphomas. (A) Gene list of all the ribosomal structural proteins (total of 82 genes) were generated and
applied for filtering the microarray data of MYC inactivation and reactivation time-course. 61 ribosomal structural proteins with p,0.01 in StepMiner
analysis are shown on the right. (B) validation of mRNA expression of ribosomal structural proteins RPS5, RPS11, RPS21, RPS24, RPS25, RPS27, RPL3,
RPL6, RPL10a, RPL24 and RPL44 by quantitative real-time PCR in osteosarcomas upon MYC inactivation and reactivation (top panel) and lymphomas
upon MYC inactivation (bottom panel). (C) Rates of protein synthesis upon MYC inactivation (bone tumors and lymphomas) and reactivation (bone
tumors) were assayed by measuring the S
35 methione and S
35 Cysteine incorporation to the protein.
doi:10.1371/journal.pgen.1000090.g004
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list or the repressed gene list generated from the pancreatic
tumors. Then, we applied StepMiner analysis to identify genes that
are permanently repressed or permanently induced with a p-
value,0.01. By comparing microarray data from two independent
MYC conditional tumor models, we found a common gene
signature with 42 genes associated with MYC-induced tumori-
genesis (Figure 9). Among the list of genes, there are 34 unique
genes positively correlating with MYC-induced tumorigenesis and
8 unique genes negatively correlating with MYC-induced
tumorigenesis in mice (Figure 9).
Boolean Analysis of Murine MYC Signature in Human
Datasets
MYC overexpression has been implicated in the pathogenesis of
many types of human cancer, in particular, hematopoietic tumors
[1]. To see if the gene signature we defined in murine tumor
Figure 5. Expression of previously published MYC targets was permanently repressed or induced upon MYC inactivation in
osteosarcomas. MYC targets collected in www.myc-cancer-gene.org were used as a list to filter the microarray data from osteosarcomas upon MYC
inactivation and reactivation. Gene expression permanently repressed (PR) or permanently induced (PI) were identified while MYC was inactivated in
bone tumors.
doi:10.1371/journal.pgen.1000090.g005
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correlated with MYC between MYC and human homologs in
human lymphomas, we retrieved all publicly available human
microarrays (n=7,171) in Affymatrix U133A platform. Then, we
classified the expression level of each gene on each array as ‘‘low’’
or ‘‘high’’ relative to a threshold using Boolean analysis ([29] and
Sahoo et al. RECOMB 2007 in press, see Figure 10A). We found
that MYC expression is ‘‘high’’ in human lymphomas (204 out of
221 lymphoma cases ignoring the ‘‘intermediate’’ values, see
Figure 10B). Figure 10B shows the gene expression scatter plot of
MYC and RPS2, which are both highly expressed in lymphoma
arrays (total of 273 lymphoma microarrays are highlighted with
red color). We then examined to see if the expression of MYC-
associated genes identified above (Figure 4 and 9) are ‘‘high’’ or
‘‘low’’ in more than 95% of the lymphoma microarrays.
The Boolean analysis identified that the expression of both small
and large ribosomal structural proteins is high in human
lymphomas (Figures S3 and S4) as was observed in murine
osteosarcomas and lymphomas (Figure 4). We further investigated
if the expression of human homologs of the common gene
signature from the murine microarray data is ‘‘high’’ or ‘‘low’’ in
human lymphomas. 63 unique probes from the induced list
(Figure 9) and 9 probes from the repressed list (Figure 9) were
found in the U133A format (see Table S9). We found 14 out of 63
probes correlated with the human arrays. Genes whose expression
was ‘‘high’’ in more than 95% of human lymphomas, whose gene
names include: BZW2, H2AFY, SFRS3, NAP1L1, NOLA2,
UBE2D2 and CCNG1 (p=4.07610
25, Figure 11). From the
repressed list of genes 4 out of 9 probes had low expression in more
than 95% of the human lymphomas, whose gene names include
LIFR, FABP3 and EDG1/HEXIM1 (p=0.03, Figure 11). We
have listed al the genes identified and their associated functions
(listed in the Swiss-Prot data base) (Figure 11). Many of these genes
have functions that could account for MYC activity. Notably,
CCNG1, LIFR and EDG1/HEXIM1 are involved in cell cycle or
signaling pathways. H2AFY and NAP1l1 are involved in
Figure 6. Expression of previously published direct MYC targets was permanently repressed or induced upon MYC inactivation in
osteosarcomas. Murine homologs of directed MYC targets identified from 3 publications [33–35] were retrieved and their expression in the bone
tumors upon MYC inactivation and reactivation was examined. Genes scored statistically significant (p,0.01) in the StepMiner analysis were labeled.
doi:10.1371/journal.pgen.1000090.g006
Gene Signature Associated with Tumorigenesis
PLoS Genetics | www.plosgenetics.org 7 June 2008 | Volume 4 | Issue 6 | e1000090modulating chromatin structures. SFRS3 and NOLA2 are
involved in mRNA and rRNA processing. BZW2, UBE2D2 and
FABP3 are involved in metabolism such as protein or fatty acid
synthesis.
Finally, we validated our results obtained by microarray analysis
through quantitative real-time PCR (Figure S5). Moreover, we
found that these identified genes exhibited similar patterns of
changes in gene expression upon MYC inactivation in our model
of MYC-induced lymphoma (Figure S6). Therefore, we have
identified a subset of MYC regulated gene products that are highly
correlated with the ability of MYC to maintain tumorigenesis.
Discussion
MYC target genes have been implicated in a multitude of
biological functions [16]. Many additional potential MYC targets
have been identified through microarray analysis [3,15,21–26,37].
However, it has not been easy to discern which if any of these
genes are involved in the ability of MYC to initiate or maintain
tumorigenesis. We have combined microarray analysis of two
conditional transgenic model systems and a human comparative
Boolean analysis to determine which of these identified genes most
strongly correlated with MYC expression from total of 273
Figure 7. Changes of MYC binding to E-box regions for genes permanently repressed upon MYC inactivation. ChIP for MYC binding to
E-box regions were examined for ribosomal structural proteins (Figure 4) and genes with the PR pattern and RR pattern expression whose homologs
were shown to be direct MYC targets before (Figure 6 and [35]). Dot plots with percentages of DNA relative to input DNA brought down by the MYC
antibody for MYC ON and MYC reactivated (48 hours) conditions in bone tumor cells are shown here (see Table S7 for the raw data, average of two
experiments). The p-values shown here were calculated by Z-test.
doi:10.1371/journal.pgen.1000090.g007
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also utilized ChIP to demonstrate that a large number of the genes
that were permanently suppressed upon MYC inactivation
exhibited changes in the ability of MYC to bind to their promoter
loci. Thus, we identified a gene signature strongly correlated with
the ability of MYC to maintain tumorigenesis. Our results have
possible implications for why MYC induces tumorigenesis in
specific cellular contexts.
To identify this gene signature, we utilized our conditional
transgenic model system of MYC-induced osteosarcoma in which
we have previously shown that upon MYC inactivation tumors
permanently lost the ability of MYC to induce tumorigenesis [6].
Thereby, we defined an initial gene signature consisting of 2,793
unique probe sets of genes that included genes whose expression
was permanently changed (Figure 3). This gene signature includes
gene products that have been already implicated as MYC targets
Figure 8. Genes associated with MYC-induced tumorigenesis in a MYC-induced pancreatic tumor model identified by the
StepMiner algorithm. Microarray data of the time-course experiments from a MYC-induced pancreatic tumor model [25] was retrieved and the
StepMiner algorithm was applied to the data to identify genes whose expression went up in tumor initiation and came down in tumor regression
(induced genes) and genes whose expression went down in tumor initiation and came back up in tumor regression (repressed genes) as potential
genes associated with MYC induced tumorigenesis in pancreatic tumors. 382 probes for induced genes and 197 probes for repressed genes with
statistically significant changes (p,0.01) are listed.
doi:10.1371/journal.pgen.1000090.g008
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strongly correlated with MYC-induced tumorigenesis in murine
osteosarcomas, lymphomas (Shachaf CM et. al. submitted) and in
human lymphomas. These results suggest that the ability of MYC
to induce ribosomal gene products is important to its ability to
initiate and maintain tumorigenesis.
Our results are consistent with a multitude of evidence
suggesting that MYC can regulate ribosomal gene expression
[15]. In Drosophila, the biological connection of MYC and
ribosomal structural proteins can also be seen in the small cell-
size phenotypes of both MYC mutants and ribosomal structural
protein genes mutants [38–40]. MYC globally regulates protein
synthesis through regulating expression of ribosomal RNAs,
tRNAs, RNA helicases, and translation elongation factors
[18,41]. Notably, it had been shown that rate of protein synthesis
was increased 3-fold in MYC-overexpressing fibroblasts compared
to MYC knockout fibroblasts [42]. We confirmed that the
inactivation of MYC in tumor cells resulted in a reduction of
both ribosomal protein gene expression and rate of protein
synthesis in murine tumor models (Figure 4). Ribosomal genes
could play important function in influencing protein translation
and thus in this manner influence the ability of MYC to function
as an oncogene. In this regard, it is notable that a recent study in
Zebra fish identified some ribosomal protein genes as tumor-
suppressors [43]. Nevertheless, it is not clear how ribosomal
structural protein genes function as tumor-suppressors during
tumorigenesis.
Interestingly, changes in the gene expression of ribosomal
structural proteins, although observed in both our model of MYC
induced osteosarcoma and lymphoma, were not seen in a model of
pancreatic islet cell tumors (Figure 4, 8, and [25]). Thus, it is
possible that ribosomal protein genes expression play a role MYC-
induced tumorigenesis only in specific types of cancer. We are
reassured of the likely importance of ribosomal gene products in
MYC associated tumorigenesis for we were able to confirm that
MYC and ribosomal structural proteins are highly correlated in
human lymphomas (Figure S4 and S5). It remains to be directly
determined if these ribosomal genes are playing a role in MYC
induced tumorigenesis.
Genes that we identified as most strongly correlated with MYC-
induced tumorigenesis (Figure 9) in mice are involved in diverse
biological processes such as transcription regulation, RNA
processing, proliferation, fatty acid transport and cell signaling
(Figure 11). Furthermore, some of the genes identified have been
previously implicated in tumors or oncogenic signaling pathways.
BLMH has been previously shown to be a MYC target [44].
Figure 9. A common gene signature associated with the ability of MYC to induce tumorigenesis in murine conditional tumor
models. Microarray data from the time-course experiment in MYC induced osteosarcoma was filtered with the list of tumor maintenance genes from
pancreatic tumors (Figure 8). 34 genes from the induced gene list and 8 genes from the repressed gene list were identified (p,0.01) as common MYC
target genes associated with MYC induced tumorigenesis in mice. Genes with E-box sequences in their promoter regions (22000 to +2000) are
labeled with red and the numbers of E-box in each gene are listed in Table S11.
doi:10.1371/journal.pgen.1000090.g009
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pathway in a microarray experiment [45]. NAP1l1 has been
shown to be a tumor marker for colon cancer [46]. TRIP13
expression was highly elevated in tumor tissues [47]. Altered
regulation of CCNG1 has been observed in breast cancer [48].
High expression of NOLA2 has been seen in squamous cell lung
cancer [49]. Interestingly, anti-tumor effects have been observed
for genes with expression reversely correlated with MYC. FABP3
has been proposed as tumor suppressor in breast cancer [50].
EDG1 has been shown to be an inhibitor for breast cancer growth
[51]. Our data now suggest that BZW2, H2AFY and SFRS3,
which function in translation initiation [52], chromatin structure
[53], and mRNA splicing [54], respectively, may also be involved
in tumorigenesis.
We were able to utilize our MYC conditional tumor models as
tools to uncover genes that are strongly correlated with tumor
maintenance. However, we recognize that it is very unlikely that
any of the individual genes we identified are sufficient alone to
explain the ability of MYC to initiate or maintain tumorigenesis.
Rather it is highly likely that it is a constellation of gene expression
changes that are responsible for the ability of MYC to maintain
tumorigenesis.
We can now offer a possible explanation for why the brief
inactivation of MYC can result in the permanent loss of the ability
of MYC to sustain tumorigenesis [6]. MYC inactivation appears to
result in permanent changes in the ability of MYC to function as a
transcription factor (Figure 12). Recently, we have shown that
MYC inactivation induced chromatin modifications associated
with cellular senescence [14]. The particular structural state of
chromatin has been shown to influence the ability of MYC to bind
to specific promoter loci [36]. Indeed, our results illustrate that
upon MYC inactivation there were permanent changes in the
ability of MYC to bind to the promoters of specific gene loci
(Figure 7). It remains to be determined the mechanism of these
changes in chromatin structure. One possibility is that MYC itself
is contributing to changes in chromatin structure through global
changes in chromatin modifications, which seems an attractive
possibility based upon the work from many laboratories
[14,20,55]. Regardless of the mechanism, our results point to
the fact that the genes that MYC can regulate are different in
different cellular contexts and that this appears to have a direct
bearing on when MYC overexpression results in a neoplastic
phenotype. We note that we could not explain all of the
permanent changes in gene expression based upon differences in
MYC binding to promoter loci. Thus, it is likely there are
additional mechanisms by which MYC’s ability to regulate gene
expression has been altered.
One of the biggest challenges in understanding how MYC
contributes to tumorigenesis has been to address the conundrum
that MYC has both direct and indirect influence on the expression
of so many different genes and these genes are involved in a
multitude of biologic functions. Many of these genes may not be
relevant to how MYC overexpression contributes to tumorigenesis.
Here we have illustrated by using a defined transgenic mouse model
that exhibits conditional tumorigenesis such that upon MYC
inactivation tumor cells permanently loses a neoplastic phenotype
that we can define a specific gene list that is specifically correlated
with MYC’s ability to maintain tumorigenesis. To perform this
analysis we combined two novel methods of gene expression
analysis, the StepMiner and the Boolean analysis, as a powerful
strategy to perform an unbiased comparative analysis of microarray
data from conditional MYC-induced tumor models and all the
available published human data with Affymetrix U133A format.
Our strategy may be generally useful for the identification of gene
signatures associated with the ability of specific oncogenes to initiate
and sustain tumorigenesis and the identification of potential new
therapeutic targets for the treatment of cancer.
Materials and Methods
Cell Culture, Doxycycline Treatment, and Rate of Protein
Synthesis
Osteosarcoma-derived cell line 1325 [6] were cultured with
DMEM medium supplemented with 10% FBS, 1% Pen/
Strep, L-Glutamine, and non-essential amino acids (Invitro-
gen). Lymphomas were cultured with RPMI medium
supplemented with 10% FBS, 1% Pen/Strep, L-Glutamine
and 3.96610
24% of 2-mercaptoethanol (Sigma). 20ng/ml of
Figure 10. Overview of Boolean analysis of gene expression in
all human microarray data with U133A format. (A) The gene
expression from all the U133A arrays was first normalized and ordered
from low to high. Each red mark represents one array data (total of
7,171 arrays). The StepMiner algorithm was then applied to define a
threshold (the red line) and an ‘‘intermediate’’ region was set with a
value of 0.5 around this threshold (blue lines). The expression above or
below the ‘‘intermediate’’ region is considered as ‘‘high’’ or ‘‘low’’,
respectively. (B) A scatter plot of MYC expression (Y axis) versus RPS2 (X
axis) is shown here. Each green mark represents one array data (total of
7,171 arrays). Red spots represent lymphomas (total of 273 arrays). The
red lines represent the thresholds and the blue lines mark the
‘‘intermediate’’ region. Other examples of Boolean analysis are shown
here (Figure S7).
doi:10.1371/journal.pgen.1000090.g010
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expression. Seven times, each time with 20 mls of PBS, was
applied to cells to completely remove doxycycline in the
medium.
For rate of protein synthesis, lymphoma-derived cell line 6780
[14] or bone tumor cell line 1325 grown in complete medium with
or without doxycycline were rinsed with PBS and then replenished
with DMEM (with or without doxycyline) without methionine and
cysteine (Invitrogen), containing 10% dialyzed fetal calf serum
(Invitrogen), 1% Pen/Strep, L-Glutamine. One hour later, cells
were labeled with 30 mCi of EXPRE
35S
35S (PerkinElmer) per
plate for 60 minutes and then washed with PBS. Cells were lysed
and TCA precipitation was applied to determine the incorporation
of radiolabeled amino acids. Aliquots of cell lysate were used for
protein determination by DC Protein Assay (Bio-Rad). The
protein synthesis rate was calculated as TCA-precipitable counts
per minute divided by micrograms of protein in the same sample.
Quantitative Real-Time PCR
cDNA were synthesized by Superscript II (invitrogen) followed
by manufacture’s protocol. Real-time PCR for human c-MYC
(probes and primers from Applied Biosystems) and mouse
GAPDH [56] were performed in ABI PRIZM analyzer.
Sequences for primers for quantitative real-time are listed in
Table S8.
cDNA Labeling for Microarray Experiments
Mouse cDNA microarrays were produced at Stanford Func-
tional Genomic Facility. cDNA labeling and hybridization were
followed as previously described [57]. Briefly, mRNA from bone
tumor cells were extracted by Trizol (Invitrogen) based on the
protocol provided by the manufacturer. 30 mg of total RNA from
bone tumor and reference RNA generated by pooling RNA from
various mouse tissues were used for each microarray experiment.
cDNA from bone tumor cells was labeled with Cy5-dUTP and
Figure 11. High correlation of expression between MYC and human homologs of genes associated with MYC-induced
tumorigenesis in human lymphomas by Boolean analysis. Expression of human homologs of genes associated with MYC-induced
tumorigenesis was examined by Boolean analysis. Scattered plots of MYC and genes from the induced list which were highly expressed in more than
95% of the lymphomas microarrays and genes from the repressed list whose expression is low in more than 95% of the lymphomas microarrays were
listed here. List of genes with biological functions are listed on the right.
doi:10.1371/journal.pgen.1000090.g011
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reverse-transcription. Labeled cDNAs were concentrated by
Microcon YM-30 (Millipore) before hybridizing with microarrays
for 16 hours at 65uC. After hybridization, microarrays were
washed and spin dry before scanned on the GenePix 40000B
Array Scanner (Axon). Raw array images were analyzed using the
GenePix 5 software (Axon). Microarray data was then submitted
to the Stanford Microarray Database (SMD) for normalization.
Data after normalization was then applied with the StepMiner
algorithm to identify changes in gene expression.
StepMiner Analysis
The StepMiner fits step functions to time-course microarray
data and provides a statistical measure of the goodness of fit [29].
The steps are placed between time points at the sharpest change
between low expression and high expression levels, which gives
insight into the timing of the gene expression-switching event.
Mathematically, steps are placed at a position that minimizes the
sum of square error and an F-statistic with appropriate degrees of
freedom is used to produce a p-value for the goodness of fit. The
StepMiner automatically characterizes the genes in to five different
groups: Up, Down, Up-Down, Down-Up and Other [29]. The
genes are primarily sorted in ascending order according to the
timing of their change and secondarily sorted in ascending order
according to their p-values.
Chromatin Immunoprecipitation (ChIP)
ChIP was performed based on the protocol provided in the kit
with some modifications (ChIP assay kit by Upstate Biotech).
Briefly, bone tumor cells were grown on the condition described
above with (MYC OFF and MYC reactivated conditions) or
without (MYC ON condition) doxycycline (20ng/ml). 48 hours
treated with doxycycline, cells were either harvested (as MYC
OFF condition) or extensively washed with PBS (see above) to
remove doxycycline in the medium. 48 hours after washing, cells
were harvested (as MYC reactivated).
Formaldehyde (Fisher) was added to the medium to a final
concentration of 1% for cross-linking at 37uC for 10 minutes.
Cross-linking was stopped by adding glycine to a final concentra-
tion of 0.125M. Cells were washed with cold PBS containing
protease inhibitors (1mM PMSF, 1 mg/ml aprotinin and 1 mg/ml
pepstatin A) and pelleted by centrifugation. Cell pellets were then
lysed in SDS lysis buffer (1% SDS, 10mM EDTA, 50mM Tris,
pH 8.1, with proteases inhibitors mentioned above). Cells were
sonicated with a Branson 250 sonicator at a power setting of 3 for
3 times with 10 sec for each sonication and the cells were cooled
down with ice for 1 min between each sonication. This condition
of sonication yielded genomic DNA fragments with a size about
100–600 base pairs. Samples were then immunoprecipitated with
c-MYC antibody (2 mg of N262 from Santa Cruz Biotech)
followed the protocol provided by the kit (Upstate Biotech).
DNA samples from the ChIP experiments were applied for
quantification by Real-time PCR (ABI PRISM 7900 HT) with
SYBR green. Promoter sequences (22000 to +2000 relative to the
transcription start sites) of murine MYC targets were retrieved
from UCSC genome browser and primers flanking the E-box were
designed by Primer3 (http://frodo.wi.mit.edu/) (Table S10).
Boolean Analysis of Human Microarray Data
Data from 7,171 publicly available raw Affymetrix U133A
human microarrays were collected from the Gene Expression
Omnibus (GEO) [58] and normalized together using the RMA
algorithm [59,60]. Thresholds were assigned for each probe set by
first sorting the expression values for that probe set on all arrays in
ascending order, and then fitting a step function to the data using
the StepMiner. This approach places the threshold cutoff at the
Figure 12. An illustration for a possible mechanism for permanent changes of gene expression upon MYC inactivation in
osteosarcomas.
doi:10.1371/journal.pgen.1000090.g012
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gene expression levels are evenly distributed from low to high, the
threshold cutoff tends to be near the mean expression level. If the
assigned cutoff for a gene is t, expression levels above t + 0.5 are
classified as ‘‘high,’’ expression levels below t20.5 are classified as
‘‘low,’’ and values between t 20.5 and t+0.5 are classified as
‘‘intermediate’’ (Sahoo et al. RECOMB 2007 in press). Two
hundred and seventy three different human Lymphoma micro-
array experiments were identified using a simple string search
‘‘Lymphoma’’ in the GEO description of the experiment. Genes
that are ‘‘high’’ or ‘‘low’’ in more than 95% of the Lymphoma
experiments were automatically discovered. Human homologs of
genes which were associated with MYC-induced tumorigenesis in
mice were selected for this manuscript.
Supporting Information
Figure S1 Western blot for MYC protein expression upon MYC
inactivation and reactivation. Western blots for anti-MYC and a-
tubulin antibodies [14] upon MYC inactivation and reactivation
are shown here.
Found at: doi:10.1371/journal.pgen.1000090.s001 (1.21 MB EPS)
Figure S2 Induced and repressed patterns of gene expression
upon MYC inactivation in osteosarcomas identified by the
StepMiner algorithm. MYC OFF arrays (MYC inactivation for
0, 4, 8, 12, 18, 24, 36, 48 hours) were selected for the StepMiner
analysis to retrieve significant changes as the ‘‘induced’’ and
‘‘repressed’’ patterns. Statistically significant changes (p,0.01)
after StepMiner analysis are shown here. Genes previously shown
to be associated with senescence are highlighted.
Found at: doi:10.1371/journal.pgen.1000090.s002 (1.75 MB EPS)
Figure S3 High expression of both MYC and small ribosomal
structural proteins in human lymphomas by Boolean analysis.
MYC expression (Y axis) and small ribosomal structural protein
expression (X axis) were plotted for all the published human
microarrays in U133A format (green marks). Red lines represent
the cutoff thresholds and blue lines mark the ‘‘intermediate’’
regions. Green marks represent all human arrays and red marks
represent arrays from lymphoma tissues.
Found at: doi:10.1371/journal.pgen.1000090.s003 (29.83 MB
EPS)
Figure S4 High expression of both MYC and large ribosomal
structural proteins in human lymphomas by Boolean analysis.
MYC expression (Y axis) and large ribosomal structural protein
expression (X axis) were plotted for all the published human
microarrays in U133A format (green marks). Red lines represent
the cutoff thresholds and blue lines mark the ‘‘intermediate’’
regions. Green marks represent all human arrays and red marks
represent arrays from lymphoma tissues.
Found at: doi:10.1371/journal.pgen.1000090.s004 (35.18 MB
EPS)
Figure S5 Validation of mRNA expression of gene signature in
MYC-induced osteosarcomas by quantitative real-time PCR.
Quantitative real-time PCR with primers specific for genes
associated with MYC induced tumorigenesis were applied to
cDNA samples upon MYC inactivation for 0, 8, 24, 48 and MYC
reactivation for 8, 24 and 48 hours in MYC induced osteosarco-
mas to validate the mRNA expression. mRNA expression was
normalized by r-tTA expression. Relative expression levels were
shown here (MYC inactivation for 0 hour was reset to 1).
Found at: doi:10.1371/journal.pgen.1000090.s005 (3.99 MB EPS)
Figure S6 Validation of mRNA expression of gene signature in
MYC-induced lymphomas by quantitative real-time PCR. Quan-
titative real-time PCR with primers specific for genes associated
with MYC induced tumorigenesis were applied to cDNA samples
upon MYC inactivation for 0, 6, 12, 24, 48 hours in MYC-
induced lymphomas. mRNA expression was normalized by r-tTA
expression. Relative expression levels were shown here (MYC
inactivation for 0 hour was reset to 1).
Found at: doi:10.1371/journal.pgen.1000090.s006 (3.08 MB EPS)
Figure S7 Examples of Boolean analysis for expression of
BUB1B vs. CCNB2 and XIST vs. RPS4Y1 in the U133A format.
Both BUB1B and CCNB2 were found to be expressed in a cell
cycle dependent manner [61,62]. Boolean analysis for all the
arrays in the U133 A format indicates a strong correlation of
expression between the two genes (left panel). XIST is expressed
from the inactivated6chromosomes [63,64]. RPS4Y1 is a
transcript from the Y chromosomes [65]. Boolean analysis for all
the arrays in the U133 A format indicates the exclusive expression
pattern between the two genes (right panel).
Found at: doi:10.1371/journal.pgen.1000090.s007 (1.86 MB EPS)
Table S1 List of LUIDs, gene names and Genbank accession
numbers of induced and repressed genes upon MYC inactivation.
Found at: doi:10.1371/journal.pgen.1000090.s008 (0.24 MB
XLS)
Table S2 List of LUIDs, gene names and Genbank accession
numbers of genes permanently repressed (PR), permanently
induced (PI), reversibly repressed (RR), and reversibly induced
(RI) upon MYC inactivation.
Found at: doi:10.1371/journal.pgen.1000090.s009 (0.37 MB
XLS)
Table S3 GO term analysis of genes permanently induced or
repressed upon MYC inactivation in osteosarcoma. Permanently
induced (PI) genes (expression went up and stayed up) and
permanently repressed (PR) genes upon MYC inactivation was
analyzed by GO Term to identify possible representative
biological processes in each time points along the time-course
for MYC inactivation. Statistically significant (p,0.01) biological
processes in each step are listed here (step 0: between MYC OFF 0
and 4 hours, step 1: between MYC OFF 4 and 8 hours, step 2:
between MYC OFF 8 and 12 hours, step 3: between MYC OFF
12 and 18 hours, step 4: between MYC OFF 18 and 24 hours,
step 5: between MYC OFF 24 and 36 hours, step 6: between
MYC OFF 36 and 48 hours).
Found at: doi:10.1371/journal.pgen.1000090.s010 (0.04 MB
DOC)
Table S4 Gene Ontology (GO) term analysis for genes with PI
patterns upon MYC inactivation. Permanently induced (PI) genes
(expression went up and stayed up) upon MYC inactivation was
analyzed by GO Term to identify possible representative
biological processes in each time points along the time-course
for MYC inactivation. Statistically significant (p,0.01) biological
processes in each step (step 0: between MYC OFF 0 and 4 hours,
step 1: between MYC OFF 4 and 8 hours, step 2: between MYC
OFF 8 and 12 hours, step 3: between MYC OFF 12 and 18 hours,
step 4: between MYC OFF 18 and 24 hours, step 5: between
MYC OFF 24 and 36 hours, step 6: between MYC OFF 36 and
48 hours).
Found at: doi:10.1371/journal.pgen.1000090.s011 (0.06 MB
XLS)
Table S5 Gene Ontology (GO) term analysis for genes with PR
patterns upon MYC inactivation. Permanently repressed genes
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was analyzed by GO Term to identify possible representative
biological processes in each time points along the time-course for
MYC inactivation. Statistically significant (p,0.01) biological
processes in each step (step 0: between MYC OFF 0 and 4 hours,
step 1: between MYC OFF 4 and 8 hours, step 2: between MYC
OFF 8 and 12 hours, step 3: between MYC OFF 12 and 18 hours,
step 4: between MYC OFF 18 and 24 hours, step 5: between
MYC OFF 24 and 36 hours, step 6: between MYC OFF 36 and
48 hours).
Found at: doi:10.1371/journal.pgen.1000090.s012 (0.08 MB
XLS)
Table S6 List of gene names with the PR and PI patterns for
three previously published reports regarding direct MYC targets
[33–35] and the RR pattern for one previously published reports
regarding direct MYC targets [35]. Murine homologs of human
direct MYC targets [33–35] were retrieved and used as a list to
filter the bone tumor microarray data. Genes with the PR, PI and
RR patterns which are statistically significant after the StepMiner
analysis are shown here.
Found at: doi:10.1371/journal.pgen.1000090.s013 (0.09 MB
XLS)
Table S7 Raw data of ChIP experiments. ChIP for MYC
binding to E-box regions were examined for ribosomal structural
proteins (figure 4) and genes with the PR pattern and RR pattern
expression whose homologs shown to be direct MYC targets
before (figure 6 and [35]). Real-time PCR was applied to measure
MYC binding to the E-box regions in the promoter of these MYC
targets upon MYC ON, MYC inactivated for 48 hours, and MYC
reactivated for 48 hours. Percentage of DNA brought down by
ChIP was calculated as shown before [19].
Found at: doi:10.1371/journal.pgen.1000090.s014 (0.21 MB
XLS)
Table S8 List of gene names which were induced (repressed) in
tumorigenesis (MYC activation) and repressed (induced) in tumor
regression (MYC inactivation) in MYC-induced murine pancreatic
tumors. The StepMiner algorithm was applied to the raw
microarray data generated from the pancreatic tumors upon
MYC activation and MYC inactivation [25]. Induced and
repressed gene lists with p,0.01 after the StepMiner analysis
are shown here.
Found at: doi:10.1371/journal.pgen.1000090.s015 (0.04 MB
XLS)
Table S9 List of Affymetrix probe IDs of human homologs of
genes associated with MYC-induced tumorigenesis in mice.
Found at: doi:10.1371/journal.pgen.1000090.s016 (0.02 MB
XLS)
Table S10 List of primer sequences and promoter sequences for
quantitative real-time PCR and ChIP.
Found at: doi:10.1371/journal.pgen.1000090.s017 (0.65 MB
XLS)
Table S11 List of numbers of E-box sequences in promoter
regions (22000 to +2000) of common murine MYC target genes.
Promoter sequences were retrieved for common murine MYC
target genes shown in figure 9 and the numbers of E-box
sequences in these regions are shown here.
Found at: doi:10.1371/journal.pgen.1000090.s018 (0.02 MB
XLS)
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